Clinical trial of carbon ion radiotherapy for gynecological melanoma
Clinical trial of carbon ion radiotherapy for gynecological melanoma
复制标题
DOI：
10.1093/jrr/rrt120
复制
发表时间：
2014-03-01
影响因子：
2
通讯作者：
Kamada, Tadashi
中科院分区：
文献类型：
--
作者：
Karasawa, Kumiko;Wakatsuki, Masaru;Kamada, Tadashi
碳离子放疗(C-ion RT)是治疗恶性黑色素瘤的先进手段。在我们于2004年11月使用C-ion RT治疗了我们的第一例妇科黑色素瘤后，我们决定进行一项临床试验，以评估其治疗妇科黑色素瘤的有效性。组织学证实的妇科区域恶性黑色素瘤以及腹股沟和盆腔区域的淋巴转移为本研究的入选标准。小盆腔，包括GTV和转移的淋巴结，接受总剂量为36GYe的照射，然后分16次给予GTV57.6GYe或GYe。2004年11月至2012年10月期间，一系列23名患者接受了治疗。患者年龄51-80岁，中位数71岁。其中14例位于阴道，6例位于外阴，3例位于宫颈。在23例患者中，22例接受了总剂量达57.6GYE的照射，1例患者接受了总剂量达57.6GYE的GYE照射。其中11例患者还接受了化疗和β-干扰素治疗。1例同时接受干扰素-β治疗的患者观察到3级或以上的急性和晚期毒性反应。中位随访时间为17个月(6~53个月)。复发14例，3年局控率49.9%，总生存率53.0%。C-ion RT可能成为妇科黑色素瘤的非侵入性治疗选择。
Carbon ion radiotherapy (C-ion RT) is an advanced modality for treating malignant melanoma. After we treated our first case of gynecological melanoma using C-ion RT in November 2004, we decided to conduct a clinical trial to evaluate its usefulness for the treatment of gynecological melanoma. The eligibility criteria for enrollment in this study were histologically proven malignant melanoma of the gynecological regions with lymph node metastasis remaining in the inguinal and pelvic regions. The small pelvic space, including the GTV and the metastatic lymph node, was irradiated with up to a total dose of 36 GyE followed by a GTV boost of up to a total dose of 57.6 GyE or 64 GyE in 16 fractions. A series of 23 patients were treated between November 2004 and October 2012. Patient age ranged from 51-80 with a median of 71. Of the tumor sites, 14 were located in the vagina, 6 in the vulva, and 3 in the cervix uteri. Of the 23 patients, 22 were irradiated with up to a total dose of 57.6 GyE, and 1 patient was irradiated with up to a total dose of 64 GyE. Chemotherapy and interferon-beta were also used to treat 11 of the patients. Acute and late toxicities of Grade 3 or higher were observed in 1 patient treated with concurrent interferon-beta. The median follow-up time was 17 months (range, 6-53 months). There was recurrence in 14 patients, and the 3-year local control and overall survival rates were 49.9% and 53.0%, respectively. C-ion RT may become a non-invasive treatment option for gynecological melanoma.